Refining antibody-drug link widens therapeutic window
http://www.macroworldinvestor.com/m/m.w?lp=GetStor [2008-7-25]
Tag : Refining Agent
Nature Biotechnology, researchers from South San Francisco biotechnology firm GenentechInc. described a way to conjugate drugs to specific amino acidresidues on antibodies that leave folding and binding of theantibodies unaffected. The method allows them to make antibody-drugconjugates that are controlled more precisely, and have unchangedefficacy but reduced toxicity relative to classically producedconjugates.
Antibody-drug conjugates possibly could be the peanut butter andchocolate of the drug world. The targeting power of antibodiestheoretically should make it possible to deliver highly toxic drugsto very specific sites in the body, making it possible to treatpatients without getting the proverbial cure that's worse than thedisease.
In practice, the best days of antibody-drug conjugates seem tostill lie ahead. In the U.S., though companies including Curagen,Seattle Genetics and Genentech itself have such conjugates inclinical trials, only one such agent, Genasense and Wyeth'sMylotarg (gemtuzumab ozogamicin), has been approved by the FDA todate.
Nature Biotechnology, researchers from South San Francisco biotechnology firm GenentechInc. described a way to conjugate drugs to specific amino acidresidues on antibodies that leave folding and binding of theantibodies unaffected. The method allows them to make antibody-drugconjugates that are controlled more precisely, and have unchangedefficacy but reduced toxicity relative to classically producedconjugates.
Antibody-drug conjugates possibly could be the peanut butter andchocolate of the drug world. The targeting power of antibodiestheoretically should make it possible to deliver highly toxic drugsto very specific sites in the body, making it possible to treatpatients without getting the proverbial cure that's worse than thedisease.
In practice, the best days of antibody-drug conjugates seem tostill lie ahead. In the U.S., though companies including Curagen,Seattle Genetics and Genentech itself have such conjugates inclinical trials, only one such agent, Genasense and Wyeth'sMylotarg (gemtuzumab ozogamicin), has been approved by the FDA todate.
Related News »
In Focus »
Chemical Restricted
Engaging in concept of environmental protection for the Green Olympics, the chemical industry ..
- U.S. team to provide all Olympic ..
- Investors eye coal-to-oil conversion ..
- Chemical education in need of reform
B2B Keywords:
International market Chinese Importer Wholesale trade Wholesale products World trade Wholesale distributors International trade Foreign trade Wholesale distributor Importers Import export business Sell online Help u sell Global trade How to market a product Online supplier Wholesale product
International market Chinese Importer Wholesale trade Wholesale products World trade Wholesale distributors International trade Foreign trade Wholesale distributor Importers Import export business Sell online Help u sell Global trade How to market a product Online supplier Wholesale product
Feature Products»
Hot Products: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0-9
-
-
About Us -
Links -
Privacy Policy -
Terms of Use -
Site Map -
Contact Us -
Call Center: 0086-95105561 © 2007 Tootoo.com -
